Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands.

Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as soon as the first dosing has started, potentially in late October. The company anticipates the final doses will be administered in late November.

To view the full press release, visit https://cnw.fm/dsWB5

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, announced the appointment of Richard Christopher as its new CEO, replacing Chris Bunka who will serve in his new capacity as Executive Strategic Advisor while remaining Chairman of the Board
• Lexaria also announced entering a Material Transfer Agreement with an undisclosed pharmaceutical industry partner, leading to speculation of which company has taken this formal step to get closer to Lexaria’s technology
• The company is focusing on this pharmaceutical industry collaboration and on investigations in cardiometabolic and GLP-1 sectors (alternative diabetes and obesity treatments), a huge sector that particularly needs its unmatched technology
• The company seems one step closer to exploiting commercial opportunities in the sector, with a goal toward associated commercialization of its patented DehydraTECH technology

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, worked on the development of its patented DehydraTECH(TM) technology. It has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. These efforts have earned it 46 patents in the United States, European Union and other countries, with many more pending worldwide (https://cnw.fm/mBfkA).

With the success achieved thus far, Lexaria is looking to pivot and focus on pharmaceutical industry collaboration and operations. To help steer it in the right direction, the company appointed Richard Christopher as its new CEO, effective Aug. 31, 2024. He will replace Chris Bunka, who will serve in his new capacity as Executive Strategic Advisor to the management team. He will continue to support and advise Lexaria and remain chairman of the board of directors.

“I’m delighted that I have been appointed to lead Lexaria,” noted Mr. Christopher. “The company is well positioned for an exciting period of growth centered around the advancement and improvement of drug delivery in the GLP-1 marketplace. We are preparing for an active and collaborative new era for Lexaria in the pharmaceutical industry,” he added (https://cnw.fm/kj2tz).

Mr. Christopher will lend his vast experience spanning more than three decades in the medical device and pharmaceutical industries. He also has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning, and capital markets. Most recently, he was the Chief Financial Officer at InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company focusing on treating spinal cord injuries.

This appointment directly followed the Material Transfer Agreement with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria’s DehydraTECH technology in a pre-clinical setting. Under the terms of the agreement, Lexaria will formulate and supply certain DehydraTECH compositions for use in animal studies. PharmaCo has been awarded a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination, and the project should be completed within roughly six months or less (https://cnw.fm/62ydz).

Lexaria is looking to double down on its DehydraTECH research and commercialization. This move points to this commitment and ushers in a new chapter for the company. Its management is optimistic about the future, not just from a commercial standpoint and creating shareholder value, but also by positively transforming human health.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study
• The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide
• The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study
• For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss
• As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study. This study explores Lexaria’s patented technology, DehydraTECH(TM), and its potential in addressing diabetes and weight loss. More importantly, it looks to establish whether DehdyraTECH processing results in higher brain absorption than non-DehydraTECH arms, with a focus on glucagon-like peptide 1 (“GLP-1”) drugs, liraglutide and semaglutide (https://cnw.fm/iAhxm).

This part of the study was comprised of eight different formulation arms. Arms A through D used different DehydraTECH-CBD compositions, with arms E and F using DehydratTECH-processed Rybelsus, and arms G and H using pure GLP-1 drugs (semaglutide and liraglutide, respectively) processed with DehydraTECH. At the eight-week mark, the liraglutide arm H posted a weight reduction of 4.74%, the most significant weight reduction from the entire study. Equally interesting, two of the DehydraTECH-CBD compositions also led to weight reductions and also outperformed both Rybelsus(R) and pure semaglutide (https://cnw.fm/iAhxm).

For Lexaria, this continued outperformance of DehydraTECH-liraglutide and DehydraTECH-CBD is of particular interest. Lexaria fully owns DehydraTECH-CBD, while liraglutide has become available in generic version. This presents a massive opportunity for Lexaria and its goal of offering a potential treatment option for diabetes and weight loss.

The global diabetes drugs market in 2023 was valued at $79.925 billion. By 2032, it is projected to hit $153.98 billion in value, representing a CAGR of 7% over the forecast period (2024-2032) (https://cnw.fm/fo3Ut). Lexaria looks to carve out a decent market share from this growth with its DehydraTECH technology, primarily by offering a viable oral treatment alternative to what is currently in the market. Its DehydraTECH technology has proven itself many times to improve drug delivery, and it has also done so in its ongoing studies. The company looks to build on this, ultimately offering an oral alternative to diabetes treatment.

As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology. They are also confident that results from the study will inch the company closer to carving out a market share in the diabetes and obesity treatment market, even as it continues to create value for its shareholders.

For company information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study
• Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology
• DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively
• These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker rats, falling in one of three study arms, with dosing lasting 12 weeks (https://cnw.fm/1u3Rj).

Two formulations posted outstanding performance from the study as of day 56 – DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B). Most notably, they each posted blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively. DehydraTECH-liraglutide specifically saw a -2.08% change as of day 28 and a -2.50% change as of day 56 in what Lexaria’s management described as “extremely interesting.”

For Lexaria, these results build on the positive results from its 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that received no treatment. For the current study, each of the eight active groups of animals either experienced a smaller increase or an actual decrease in blood sugar level relative to baseline compared to the obese control group in the previous study.

The ongoing study featured eight groups. Groups A through D were administered with different DehydraTECH-CBD compositions. Groups E and F utilized reformulated Rybelsus DehydraTECH compositions, whereas groups G and G used pure glucagon-like peptide-1 (“GLP-1”) drugs semaglutide and liraglutide respectively in DehydraTECH compositions. Additional results from this study are expected soon. However, Lexaria’s management remains optimistic that it will replicate both the interim and previous results, ultimately demonstrating the superiority of its DehydraTECH technology.

The global diabetes treatment market was valued at $79.25 billion in 2023. It is projected that by 2032, it will have surpassed $153 billion in valuation, mainly influenced by the growing prevalence of the condition and the increasing demand for effective drug therapies (https://cnw.fm/WhvWz). For the longest time, treatment options have involved painful injections, which, to many, have been a source of discomfort and, to some, an outright deterrent. Lexaria looks to carve out a piece of the diabetes treatment market share by offering an oral alternative and is banking on its DehydraTECH technology to achieve that. Its previous and ongoing studies are a testament to its commitment to this goal and its pledge to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were the top performers in the study at day 56, reducing blood sugar levels by 2.50%, 1.90% and 1.53% respectively. These results appear to support Lexaria’s belief that DehydraTECH-CBD may have utility, particularly if used together with a GLP-1 drug, in diabetic control.

Additionally, select DehydraTECH-CBD formulations showed apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks, while DehydraTECH-liraglutide showed apparent superiority to DehydraTECH-semaglutide. Animal testing of the combination of DehydraTECH-CBD with DehydraTECH-GLP-1 drugs is ongoing and in the final phases of the study, with additional results expected soon.

To view the full press release, visit https://cnw.fm/6EdX5

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drugs.
• GLP-1 drugs have shown great promise in addressing diabetes and obesity, with nearly all the major brands administered only through injection devices.
• A previous human study by Lexaria evidenced improved bioavailability when semaglutide was administered orally, as compared to standard Rybelsus®.
• Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP1 market.

Data from the United States shows that 54% of adults and 66% of children consume more added sugars than recommended (https://cnw.fm/JNFjW). On average, it has been noted that adults, young adults, and children in the United States consume 17 teaspoons of added sugar daily, which is more than two to three times the recommended amount for men and women, respectively. Extrapolated annually, this adds up to around 60 pounds of added sugar or six 10-pound bowling balls (https://cnw.fm/VamC5).

Numerous studies have linked increased sugar consumption to diabetes. While not directly linked, sugar is considered integral to weight gains, which, in turn, increases their risk of type 2 diabetes. The condition cannot be cured, but it can be managed. Recent studies on glucagon-like peptide-1 (“GLP-1”) have shown great promise in addressing the condition. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the potential of these GLP-1 drugs, and if any of its recent studies are anything to go by, the company is on track to offer an oral delivery enhancement to current GLP-1 options that are in the market today.

People living with diabetes often require insulin shots to manage their condition. Although many types of insulin are available, including long-acting, rapid-acting, and short-acting, none of those can be taken orally to lower blood sugar. This is because stomach enzymes have been shown to interfere with insulin’s action, prompting the use of needles and syringes, or an insulin pen, to deliver the product to the body (https://cnw.fm/utYCj). This has also been the case for GLP-1 drugs.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/Aaqa0).

Lexaria has explored oral delivery of GLP-1 drugs using its patented DehydraTECH(TM) technology since the beginning of the year. So far, its studies have evidenced increased bioavailability, with its WEIGHT-A24-1 diabetes animal study showing a stark decrease in the rate of body weight gain for specific DehydraTECH-CBD formulations and noticeable weight loss for its DehydraTECH-Liraglutide (https://cnw.fm/pHYrf). All of its studies thus far have highlighted DehydraTECH’s potential in treating diabetes and obesity, and the company looks to double down on this research for the remainder of the year.

As the conversation about added sugars, diabetes, and obesity proliferates, the company’s management is optimistic about its ongoing GLP-1 studies. It is also confident that the studies will yield positive results, demonstrating the superiority of DehydraTECH as a drug delivery technology. As a company, Lexaria has already validated the technology’s usefulness in delivering various orally administered bioactive molecules more effectively. Its focus on GLP-1 drugs for the potential treatment of diabetes and obesity speaks to the company’s confidence in the technology and its commitment to stamping its position as a leader in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• The company provided updates for its study programs for 2024, with a focus on its glucagon-like peptide-1 (“GLP-1”) agonist research program, targeting a significant step up in addressing worldwide diabetes and obesity, a tremendous market
• Lexaria has its Human Pilot Study #3 lined up, as well as its chronic dosing human study, both studies will begin dosing later this year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings (https://cnw.fm/OxPux).

Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (“GLP-1”) agonist research program. GLP-1, a class of drugs, has demonstrated an ability to significantly address diabetes and obesity. What Lexaria’s unique drug delivery platform offers is the added ability to greatly improve the otherwise poor oral bioavailability of GLP-1 drugs, making it possible for simple oral application versus traditional injection, an opportunity of huge implication in the marketplace.

Human pilot study #1, utilizing Novo Nordisk’s(R) semaglutide (Ozempic(R), Rybelsus(R)) was reported on in January 2024, and human pilot study #2, using the same drug, is expected to be reported on in August and September, 2024.

Lexaria has made notable progress, having commenced another research program, the completion of which is set for August. This program will be executed by the National Research Council of Canada (“NRC”). It will seek to evaluate the molecular properties of DehydraTECH-processed pure semaglutide using simulated gastric fluid, which mimics conditions in the human gut.

Lexaria also looks to follow through with its chronic (12-week) dosing human study set to be carried out in Australia. This study, which will involve 70-90 human study subjects with pre-diabetic and Type 2 diabetic conditions, will be run in Australia, and preparations have already begun. It will leverage the use of Rybelsus as a positive control, and then in four additional separate arms, DehydraTECH-processed 1) semaglutide, 2)CBD, 3) tirzepatide, and 4) combo CBD plus semaglutide This larger study will be registered as a Phase 1 level study and carried out into 2025.

Human Pilot Study #3 is also in the pipeline, a study that will enroll up to eight healthy human volunteers, intending to evaluate DehydraTECH’s effectiveness in combination with a dual action GLP-1 agonist and glucose-dependent insulinotropic peptide (“GIP”) drug, Eli Lilly’s(R) well-known tirzepatide. The study will aim for several endpoints, including blood sugar, pharmacokinetics, and tolerability. Already, the company has brought a contract research organization (“CRO”) to run the study and is expecting to begin dosing in September.

Lexaria is bullish about its GLP-1 studies, since revenues for this product class exceeded $31 billion, with the market projected to grow significantly in the coming years. The company continues to make progress toward this extremely high-value target.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs
• The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity
• Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition

According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and 79 globally have diabetes. In addition, almost half of them are unaware that they are living with the condition. The Federation further projects that by 2045, one in eight adults in the world will be living with diabetes. This will represent approximately 783 million people, an increase of 46% from the current numbers (https://cnw.fm/QsqcW).

The figures in the United States are just as startling, with 38.4 million people of all ages, or 11.6% of the country’s population having diabetes, according to the Centers for Disease Control (“CDC”) (https://cnw.fm/dHQHL). Also, a Population Health Management report shows estimates that, by 2030, over 54.9 million Americans will have diabetes, representing a 54% increase between 2015 and 2030 (https://cnw.fm/2oSYS). These statistics have prompted organizations and societies to initiate and sustain conversations around diabetes and its management.

They have also pushed organizations to explore ways to manage the condition better, and one that has stood out is Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. Lexaria looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. Testing conducted since 2016, has demonstrated the technology’s ability to increase bio-absorption. It has even evidenced an ability to deliver some drugs more effectively across the blood-brain barrier, with its range of applications scaling across bioactive molecules, oral cannabinoids, and other active pharmaceutical ingredients (“APIs”).

Lexaria has recently made strides with glucagon-like peptide-1 (“GLP-1”) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. In the last month, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of semaglutide, the GLP-1 drug used in the study, and tolerability. The study also measured blood glucose and insulin levels, ultimately serving as an indicator in the potential treatment of diabetes and weight loss (https://cnw.fm/U3UGj).

GLP-1 drugs have been lauded for their potential to treat diabetes. However, when consumed orally, the stomach’s acidic environment seriously degrades its bioavailability, resulting in meager blood absorption rates of less than 1%, which is far from ideal. This has restricted their administration to painful injections, which can be a deterrent to some people.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/C1osG).

With Lexaria’s DehydraTECH technology, increased bioavailability has been evidenced, bringing the company closer to offering a viable alternative to injectable delivery of GLP-1 drugs. In addition, the studies conducted so far have shown better tolerability of the GLP-1 drugs used, mainly Rybelsus(R), further pointing to the technology’s superiority and highlighting its potential in treating weight loss and diabetes.

Lexaria recognizes a market opportunity with its technology. It also recognizes a growing problem that needs to be addressed sooner rather than later. For a market valued at $79.3 billion in 2023, the company looks to create significant additional value for its shareholders (https://cnw.fm/WWCjR). As it continues with its GLP-1 studies, its management is optimistic about their outcome.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study
• The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market
• The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy”
• It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim results from its WEIGHT-A24-1 animal study. The study evaluated the company’s patented DehydraTECH technology and its potential to address diabetes and weight loss. The first four weeks of dosing was successful, with Lexaria’s management describing its findings as “noteworthy” (https://cnw.fm/nRqEL).

The first phase of this study involved eight study arms, four of which used varying compositions of DehydraTECH-processed CBD. Two of the arms used reformulated Rybelsus(R) composition, which included DehydraTECH and sodium salcaprozate (“SNAC”) technology. In contrast, the last two used pure GLP-1 drugs, primarily semaglutide and liraglutide, respectively, without SNAC inclusion. This marked the first time Lexaria has used liraglutide in any glucagon-like peptide-1 (“GLP-1”) study.

“This is the first time that DehydraTECH processing was applied to the GLP-1 drug liraglutide, and it is encouraging to witness its relative outperformance,” noted Lexaria’s official reporting on the findings.

Over the course of the study, unlimited food and water were provided to the animals. In the initial acclimation phase, 34 days before the beginning of dosing, the animals gained 10.9% body weight on average. During the subsequent 28 days of dosing, all animals showed either a noticeable decrease in the rate of body weight gain or the beginning of weight reduction. Most notably, DehydraTECH-liraglutide and DehydraTECH-CBD produced the most significant weight loss results at -1.58% and -1.50%, respectively.

For Lexaria, this marks a significant milestone, not just with using liraglutide in its studies but also in closing the first eight study arms and evaluating results from the first 28 days of dosing. An additional 56 days of dosing remains across all treatment groups.  Its management is optimistic about upcoming results, with the confidence that the progress achieved will be integral in shaping the outcome of future studies.

Dosing for Cohort 2 of the study has already begun and is expected to be completed in mid-October. This Cohort will feature four study arms, including a positive control arm, a placebo arm, a combined DehydraTECH-semaglutide with DehydraTECH-CBD arm, and a combined DehydraTECH-liraglutide with DehydraTECH-CBD.

This study affirms the company’s focus on both medium-term and longer-term strategies. Its management is optimistic about this undertaking and looks to follow through with it within its set timelines.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

• Considered intangible assets, patents offer a significant competitive advantage and value for companies
• Lexaria Bioscience views its growing patent portfolio as a solid foundation upon which to build future commercial partnerships
• The company recently announced the receipt of three new patents in the E.U., Canada, and the U.S.
• The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide

Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. Strong patents covering this important technology are a critical factor for Lexaria.

A robust patent portfolio has always been a metric that investors use to judge a biotechnology or biopharmaceutical company. “A strong patent position is not only an important goal for a successful biotechnology business but also the primary asset by which a company will be valued during all stages of its development. Therefore, a patent portfolio must be as well designed and solidly constructed from the outset as all other aspects of the business,” a 2001 article conveyed (https://cnw.fm/1mIaw).

Not much has changed since the article’s publication, with a recent Forbes write-up observing that intangible assets, which include trade secrets, proficiency and expertise, trademarks, copyrights, and patents, accounted for 90% of the S&P 500’s total assets in 2020. This is a substantial increase from 1975’s figures, when intangible assets only accounted for 17% of the total assets, while tangible assets comprised the balance. The article noted that the explosion of intangible assets shows “that there is value to companies’ intellectual property (“IP”),” with patents holding the potential to be “far more valuable than physical assets” because they can offer businesses a competitive advantage (https://cnw.fm/vd9Au).

For its part, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, looks at the value of its growing patent portfolio not only from a commercialization perspective but also from an IP protection standpoint. As CEO Chris Bunka put it in his 2024 letter to shareholders, “Those patents, when granted, can form the foundation upon which future commercial relationships are built” (https://cnw.fm/uBi8c).

The company recently received three new patents in the European Union (“E.U.”), Canada, and the United States (https://cnw.fm/WII23). In the EU, Lexaria received a newly granted patent in its patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This patent is validated in Austria, the Czech Republic, France, the U.K., Germany, Italy, Poland, Spain, Sweden, and Switzerland. It is the company’s second patent in this family, following receipt of the first patent in Canada.

In Canada, Lexaria received a new patent granted in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. It is the company’s fourth granted patent in this patent family and follows the receipt of a patent-granted status in the U.S., Australia, and Japan. Across the border in the U.S., Lexaria received its fourth granted U.S. patent in the patent family #24: Compositions and Methods for Treating Epilepsy.

The latter two patents granted in Canada and the U.S. build on the company’s research development initiatives and safeguard discoveries thereof. In 2021, Lexaria conducted research under its antiviral drug program, evidencing its patented DehydraTECH(TM) technology increased the delivery of five compounds from three antiviral classes into the bloodstream. The studies found that the drug-delivery improvement rates ranged between 42% and 204% (https://cnw.fm/DYgMn).

In addition, Lexaria in 2022 completed an animal seizure study that demonstrated that DehydraTECH-processed cannabidiol (“CBD”) resulted in enhanced seizure-inhibiting performance compared to Epidiolex(R), one of the world’s leading anti-seizure drugs. According to the company, the study’s results demonstrated the ability of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and to, in some instances, even surpass the performance of Epidiolex  (https://cnw.fm/EZw0Y).

The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide. The company nonetheless continues to expect additional patents to be awarded in the future, given that it retains many valid patent applications throughout the world.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN